Earnings Results: Gilead earnings slammed by legal settlement, stock falls

This article was originally published on MarketWatch

Gilead Sciences Inc. beat Wall Street’s expectations for revenue in the fourth quarter, but the drugmaker’s earnings were hit by $2 billion in unexpected costs, most of it due to a legal settlement.